- Conditions
- Sickle Cell Disease
- Interventions
- SelG1, Placebo
- Drug
- Lead sponsor
- Reprixys Pharmaceutical Corporation
- Industry
- Eligibility
- 16 Years to 65 Years
- Enrollment
- 198 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 46 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 913–936
of 17,144
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metastatic Melanoma
- Interventions
- RAF265
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 10
- States / cities
- Aurora, Colorado • Augusta, Georgia • Baltimore, Maryland + 5 more
- Conditions
- Multiple Sclerosis
- Interventions
- Placebo, 10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP), 15 mg fampridine-SR (4-aminopyridine, 4-AP), 20 mg fampridine-SR (4-aminopyridine, 4-AP)
- Drug
- Lead sponsor
- Acorda Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 19 more
- Conditions
- Beta Lactam Allergy, Hematologic Malignancy
- Interventions
- RENEW-IN Algorithm for assessment of a beta-lactam intervention, EMR Review
- Diagnostic Test · Other
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3,800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Parkinson's Disease, Sleep Fragmentation
- Interventions
- Deep Brain Stimulation
- Device
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 2
- States / cities
- Omaha, Nebraska • Philadelphia, Pennsylvania
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Interventions
- Rucaparib, Placebo
- Drug
- Lead sponsor
- pharmaand GmbH
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 564 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 22
- States / cities
- Tucson, Arizona • Fullerton, California • Sacramento, California + 18 more
- Conditions
- Turner Syndrome
- Interventions
- estrogen, androgen, placebo
- Drug · Other
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 10 Years to 14 Years · Female only
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1992 – 2012
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Philadelphia, Pennsylvania
- Conditions
- Acute Sinusitis, Streptococcal Pharyngitis, Pneumonia, Viral Infection
- Interventions
- Antimicrobial Stewardship Bundle
- Behavioral
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- Not listed
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Pamrevlumab, Placebo, Corticosteroids
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 6 Years to 11 Years · Male only
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 27
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 24 more
- Conditions
- Traumatic Brain Injury
- Interventions
- Not listed
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 7
- States / cities
- San Francisco, California • Miami, Florida • Boston, Massachusetts + 4 more
- Conditions
- Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
- Interventions
- Pulmonary Artery-First Surgical Technique, Biospecimen Collection
- Procedure
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 4
- States / cities
- Abington, Pennsylvania • Philadelphia, Pennsylvania • Willow Grove, Pennsylvania
- Conditions
- Opioid-use Disorder, Mental Health Conditions
- Interventions
- Collaborative Care for Opioid Use Disorders and Mental Health Conditions, Augmented Usual Care, Collaborative Care for Opioid Use Disorders and Mental Health Conditions Plus Certified Recovery Specialists
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 567 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipatasertib, Magnetic Resonance Imaging, Paclitaxel
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 207
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 167 more
- Conditions
- DM1, Myotonic Dystrophy, Myotonic Dystrophy 1, Myotonia, Myotonic Dystrophy Type 1 (DM1), Dystrophy Myotonic, Myotonic Disorders, Steinert Disease, Steinert, Myotonic Muscular Dystrophy
- Interventions
- AOC 1001 (del-desiran), Placebo
- Drug
- Lead sponsor
- Avidity Biosciences, Inc.
- Industry
- Eligibility
- 16 Years to 65 Years
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 18
- States / cities
- Stanford, California • Denver, Colorado • Gainesville, Florida + 15 more
- Conditions
- HeartMate II Pump Thrombosis
- Interventions
- Clinical Management Recommendations for reducing pump thrombosis
- Other
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- Not listed
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 23
- States / cities
- Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 17 more
- Conditions
- Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myelomonocytic Leukemia (M4), Childhood Acute Basophilic Leukemia, Childhood Acute Eosinophilic Leukemia, Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Minimally Differentiated Myeloid Leukemia (M0), Childhood Acute Monoblastic Leukemia (M5a), Childhood Acute Monocytic Leukemia (M5b), Childhood Acute Myeloblastic Leukemia With Maturation (M2), Childhood Acute Myeloblastic Leukemia Without Maturation (M1), Childhood Acute Myelomonocytic Leukemia (M4), Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
- Interventions
- idarubicin, cytarabine, bortezomib, etoposide, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 77
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 72 more
- Conditions
- Osteosarcoma
- Interventions
- Biospecimen Collection, Laboratory Biomarker Analysis, Questionnaire Administration
- Procedure · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 18 Years to 50 Years · Male only
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 93
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 76 more
- Conditions
- Pancreatic Cancer
- Interventions
- paclitaxel, radiation therapy
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2005
- U.S. locations
- 218
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 167 more
- Conditions
- Extensive Stage Lung Small Cell Cancer
- Interventions
- Ivonescimab 10 mg/kg, Ivonescimab 20 mg/kg
- Drug
- Lead sponsor
- PrECOG, LLC.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 13
- States / cities
- Miami, Florida • Chicago, Illinois • Baltimore, Maryland + 10 more
- Conditions
- Alcoholism
- Interventions
- Varenicline, Placebo
- Drug
- Lead sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 7
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • Bedford, New Hampshire + 4 more
- Conditions
- Ovary Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer
- Interventions
- Senaparib, Temozolomide
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Philadelphia, Pennsylvania
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Interventions
- etoposide, pegylated liposomal doxorubicin hydrochloride
- Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 62
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 49 more
- Conditions
- Breast Cancer
- Interventions
- Atezolizumab, Trastuzumab Emtansine, Placebo, Trastuzumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2034
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Buena, California • Santa Monica, California + 19 more
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Nivolumab 240 mg IV every 2 weeks + Cabiralizumab 4 mg/kg IV every 2 weeks, Nivolumab 240 mg IV every 2 weeks + BMS-986253 1200 mg IV every 2 weeks, Nivolumab 240 mg IV every 2 weeks
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 2
- States / cities
- New York, New York • Philadelphia, Pennsylvania